Skip to main content

Clinical TrialsSearch 1M+ trials from global registries Drug IntelligenceFollow pipelines from discovery to approval

Global ApprovalsTrack regulatory decisions across 12+ agencies

US FDA Drugs EU EMA Drugs Singapore HSA Drugs China NMPA Drugs Australia TGA Drugs Canada HC Drugs Spain CIMA-AEMPS Drugs UK EMC Drugs Saudi SFDA Drugs Malaysia NPRA Drugs Philippines FDA Drugs Kenya PPB Drugs

AI-Powered ResearchDiscover powerful insights with advanced AI analysis tools for clinical trials.Learn more →Premium AccessGet unlimited access to our comprehensive pharmaceutical database and analytics.Subscribe →

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

锐可博 - NMPA Drug Approval Details

Approvals/NMPA/Imipenem, Cilastatin Sodium and Relebactam for Injection

Approved

化学药品

Imipenem, Cilastatin Sodium and Relebactam for Injection

Merck Sharp & Dohme BV🇨🇳 National Medical Products Administration

Approval Date: Dec 11, 2024
Approval ID: 8f0QjXS9iN1
Company: Merck Sharp & Dohme BV
Type: 化学药品

Approval Details

Approval Id: 8f0QjXS9iN1
Approval Number: 国药准字HJ20240140
Generic Name: 注射用亚胺西瑞
Generic Name En: Imipenem, Cilastatin Sodium and Relebactam for Injection
Trade Name: 锐可博
Drug Type: 化学药品
Dosage Form: 注射剂
Strength: 1.25g（C₁₂H₁₇N₃O₄S 0.5g，C₁₆H₂₆N₂O₅S 0.5g与C₁₂H₂₀N₄O₆S 0.25g）
Reg Date: 2024-12-11
Expired Date: 2029-11-30
Company Name: Merck Sharp & Dohme BV
Production Company Name: Merck, Inc.
Company Detail Path: /organization/26790a8059eb4c1e/merck-sharp-and-dohme-bv
Production Company Detail Path: /organization/c5c961301a431d5a/merck-inc

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Dec 11, 2024

Approval ID

8f0QjXS9iN1

Type

化学药品

Back to NMPA Approvals